The lipid mediator S1P has received significant attention as an extracellular factor that signals via G protein-coupled receptors to regulate lymphocyte traf ficking and vascular function (Blaho and Hla, 2011; Cyster and Schwab, 2012; Obinata and Hla, 2012) . It is now es tablished that an S1P gradient exists between vascular and nonvascular com partments (Schwab et al., 2005; Hla et al., 2008) . High levels of S1P are found in blood and lymph, whereas the actions of degradative enzymes in tissue compartments such as secondary lym phoid organs keep its concentration low. This S1P gradient is necessary for the directional egress of lymphocytes from secondary lymphoid organs and the thymus into the circulatory system. Interference with the gradient by phar macologic or genetic manipulation of Recent work has highlighted the multitude of biological functions of sphingosine 1-phosphate (S1P), which include roles in hematopoietic cell trafficking, organization of immune organs, vascular development, and neuroinflammation. Indeed, a functional antagonist of S1P 1 receptor, FTY720/Gilenya, has entered the clinic as a novel therapeutic for multiple sclerosis. In this issue of the JEM, Zhang et al. highlight yet another function of this lipid mediator: thrombopoiesis. The S1P 1 receptor is required for the growth of proplatelet strings in the bloodstream and the shedding of platelets into the circulation. Notably, the sharp gradient of S1P between blood and the interstitial fluids seems to be essential to ensure the production of platelets, and S1P appears to cooperate with the CXCL12-CXCR4 axis. Pharmacologic modulation of the S1P 1 receptor altered circulating platelet numbers acutely, suggesting a potential therapeutic strategy for controlling thrombocytopenic states. However, the S1P 4 receptor may also regulate thrombopoiesis during stress-induced accelerated platelet production. This work reveals a novel physiological action of the S1P/S1P 1 duet that could potentially be harnessed for clinical translation.
S1P lyase (Schwab et al., 2005) , genetic knockout of sphingosine kinases (Pham et al., 2010) , S1P transporter (Spns2; Fukuhara et al., 2012) , or the lipid phos phate phosphatase3 (LPP3; Bréart et al., 2011) results in the attenuation of lym phocyte egress, and lymphopenia. Sim ilar mechanisms may also be operative in the trafficking of dendritic cells, NKT cells, and hematopoietic progenitor cells (Massberg et al., 2007; Cyster and Schwab, 2012) . These findings attest to the generality of the S1P gradient dependent trafficking paradigm for lym phocytes and other hematopoietic cells.
Detailed investigations of S1P re ceptors have also shown that S1P 1 receptor on immune cells is required for liganddependent egress (Grigorova et al., 2009; Allende et al., 2010) . The rate of egress is determined by the net effect between retention signals and egress signals. In the case of lymph node-resident T cells, a key retention signal is determined by the chemokine CCL21 signaling via CCR7 (Pham et al., 2008) . Activation of S1P 1 by S1P appears to be the only egress signal identified to date. Intravital twophoton fluorescence microscopy studies have shown that S1P 1 signaling on immune cells allows probing of the endothelial lining of cortical sinuses with cellular processes that ultimately allows pro ductive egress. The endothelial S1P 1 receptor appears to be dispensable for egress, whereas plasma membrane resi dence of S1P 1 on lymphocytes is one of the key factors that determine egress rates (Thangada et al., 2010) . It is likely that such mechanisms are applicable to many situations in which hematopoi etic cells traffic into the S1Prich envi ronments via transendothelial egress.
S1P and platelets
Early work identified that S1P is re leased by activated platelets stimu lated with thrombin or ADP (Yatomi et al.1995 (Yatomi et al. , 1997 . Platelets carry endo thelial cellprotective cargo (trophogens) such as plateletderived growth factor (PDGF), vascular endothelial growth factor, CXCL12, fibroblast growth fac tor (FGF), and stem cell factor, among others, and thrombocytopenic states lead to vascular endothelial dysfunction and breach of vascular barrier (Nachman and Rafii, 2008) . S1P seems to "nourish" the endothelium, supporting the integ rity of the vascular bed by activating endothelial S1P 1 receptors. In addition, platelets also express S1P receptors; however, their role in platelet biology has remained elusive. Zhang et al. (2012) report that S1P signaling via its multifunctional recep tor S1P 1 is important in platelet pro duction from megakaryocytes. Even though multiple S1P receptors are ex pressed in megakaryocytes (i.e., S1P 1,2,4 ), S1P 1 is unique in that it is required for two specific events important in platelet formation and release. poiesis was slightly delayed in S1pr4 KO mice in this study, suggesting a possible function under accelerated platelet gener ation. Further, a significant number of S1pr4 KO megakaryocytes exhibited ab normal cellular morphology charac terized by cytoplasmic vacuolation and nuclear ploidy changes. In contrast, S1pr4 KO megakaryocytes did not exhibit alter ations in proplatelet generation in vitro. Thus, S1P 4 may also have a role in throm bopoiesis, even though its exact signifi cance in physiological and stressinduced thrombopoiesis needs further elucidation.
Recent studies also show that S1P 1 is intimately involved in flowdependent signal transduction in the endothelium (Jung et al., 2012) . In vascular endothelial cells, S1P 1 is necessary for shear stressinduced signaling events, which culmi nate in the stabilization of newly formed vascular networks (Gaengel et al., 2012; Jung et al., 2012) . Notably, S1P 1 GPCR megakaryocyte interactions is not well understood. However, S1P 1 is known to activate the Gi pathway exclusively (Windh et al., 1999) . This results in activa tion of Racdependent cortical actin as sembly (Lee et al., 2001 ). In addition to inducing actin cytoskeleton rearrange ment, the S1P 1 -Rac pathway also po tently induces microtubule dynamics (Paik et al., 2004; Obinata and Hla, 2012) . Therefore, S1P 1 dependent Rac activa tion is critical for process extension and the release of proplatelets. Indeed, a small molecule inhibitor of Rac potently blocked platelet release.
A previous study examined S1P 4 , an other megakaryocyteexpressed S1P re ceptor that possesses different signaling properties (Golfier et al., 2010) . This receptor is strongly induced in mega karyocyte differentiation, but upon gene deletion, platelet numbers were not al tered. However, stressinduced thrombo
The positioning of megakaryocytes to the endothelial lining of the bone marrow sinusoids via the VCAM1/VLA4 adhesion pair is known to be critical for thrombopoiesis (Hamada et al., 1998; Majka et al., 2000; Avecilla et al., 2004; Schulze et al., 2006) . In S1P 1 knockout megakaryocytes, the positioning itself was not altered; however, the directional migration of proplateletcontaining cy toplasmic extensions into the circula tory compartment was inhibited. These data, coupled with in vitro studies using S1P gradients, suggest that compart mentalized S1P 1 signaling is important for directional growth of proplatelet containing megakaryocyte processes. S1P 1 signaling is also required for the shed ding of proplatelets in a Racdependent manner. Because it is well established that S1P 1 couples to the G i dependent Rac activation (Lee et al., 2001) , the findings suggest that active signaling by this S1P receptor is required to complete the final stages of thrombopoiesis (Fig. 1) . The importance of this pathway was demonstrated in the hematopoietic specific S1pr1 knockout mice, which showed severe thrombocytopenia.
These findings also highlight the cooperative action of different GPCRs in megakaryocytes in ensuring optimal thrombopoiesis. Previous studies have determined that endothelial cell ex pression of CXCL12 and its action on megakaryocytes via CXCR4 GPCR is important for the interaction and posi tioning of the mature megakaryocytes in their proper vascular niche (Avecilla et al., 2004) . Indeed, provision of CXCL12 and FGF4 (another endothelialactive cytokine; Konishi et al., 1996) was able to support platelet formation even in thrombopoietin knockout mice. Thus, CXCR4 supports megakaryocyte in teraction and positioning at the vascular niche, whereas S1P 1 supports polarized proplatelet process formation and release into the circulation.
The intracellular signaling mecha nisms used by CXCR4 in megakaryo cytes to allow interaction with endothelial cells are not well understood. The CXCR4 receptor can activate multiple G proteins, such as G i , G q , and G 12/13 (Alkhatib, 2009 ). How such pathways lead to endothelial- Figure 1 . S1P 1 receptor on megakaryocytes is required for thrombopoiesis. The S1P 1 receptor, which activates the G i protein, Ras GTPase, PI-3-kinase (PI3K), and phospholipase C (PLC) pathways, regulates the formation of proplatelet-containing cytoplasmic protrusions and release of platelet fragments. CXCR4 expression is required to position mature megakaryocytes in the appropriate vascular niche for platelet formation, and S1P 1 receptor is essential for process formation and proplatelet release. Both actin-based and microtubule cytoskeleton changes may be required for such events, which are likely to require both plasma-derived S1P and shear forces exerted by blood flow. The S1P 4 receptor may also regulate thrombopoiesis because it is also highly expressed in megakaryocytes. However, endothelial S1P 1 is essential for vascular stability and homeostasis. Several clinical conditions are associ ated with thrombocytopenia. In various infectious conditions, such as sepsis and Dengue hemorrhagic fever, platelet counts are markedly reduced and pose a significant risk for hemorrhage. Thus, in many hematological malignancies, as well as after administration of bone mar row cytotoxic therapies, the ability to in crease platelet counts acutely may be useful. Thus, activation of this pathway with a longlasting agonist of S1P 1 may be beneficial not only in increasing plate let counts but also in preserving endo thelial function. It is important to note that current S1P 1 receptor modulators act as functional antagonists because of their ability to induce irreversible receptor internalization (Oo et al., 2011) . In this scenario, such compounds are unlikely to be effective inducers of platelet formation. Thus, a new generation of S1P 1 agonists will need to be developed to therapeuti cally harness this system. Because the S1P pathway is involved in the terminal steps of thrombopoiesis, it is likely that S1P 1 agonists will have to be used in conjunc tion with other inducers of thrombopoie sis, for example, thrombopoietin, a key megakaryocyte differentiation factor.
These recent findings of Zhang et al. (2012) have highlighted a novel function of the lipid mediator S1P that signals through its multifunctional receptor S1P 1 . This pathway may be potentially useful in therapeutic modulation of thrombocyto penia. However, because of the multitude of biological systems that S1P 1 regulates, any therapeutic strategy will need to con sider possible adverse events. Novel agents that selectively target S1P 1 receptors in a cell or tissuespecific manner will likely be needed to fully harness this potential translational opportunity. can signal in response to laminar shear stress in a ligandindependent manner. Either the S1P 1 GPCR itself contains a mechanosensitive domain or is capable of associating with a mechanosensor, thus promoting signal transduction in a ligandindependent manner (Jung et al., 2012) . Therefore, it is possible that proplatelet release from the transendo thelial processes into the circulation requires S1Pdependent and flow dependent mechanisms.
S1P therapeutics and potential modulation of platelet biology
The ability of the S1P-S1P 1 axis to regu late immune cell trafficking was harnessed in the novel treatment paradigm for mul tiple sclerosis (MS), in which autoreactive immune cells migrate into the central ner vous system (CNS) and destroy myelin containing axons, leading to astrogliosis and neuronal deficit. Treatment of MS pa tients with the S1P1 receptor antagonist Fingolimod (a.k.a., FTY720/Gilenya) re sulted in the disruption of normal traf ficking patterns as indicated by the reduced numbers of circulating cen tral memory type T cells that are IL17 + (LaMontagne et al., 2006; Brinkmann et al., 2010; Cohen et al., 2010) . In mouse models of experimental autoimmune en cephalomyelitis, S1P 1 receptor inhibitors induced profound lymphopenia and re duced penetration of inflammatory cells into the CNS (Chun and Hartung, 2010) . Fingolimod and related S1P 1 receptor targeting drugs are functional antagonists; even though they act as agonists upon ini tial binding to S1P 1 , they induce irrevers ible receptor internalization, resulting in a reduced plasma membrane residence of S1P 1 (Oo et al., 2011) . Zhang et al. (2012) show that FTY720 administration causes a rapid increase in platelet numbers in mice, suggesting that acute agonistic action of FTY720 on the megakaryocyte S1P 1 receptors induced platelet release. Thus, it may be possible to therapeuti cally regulate platelet deficiencies by targeting S1P 1 . However, because this pathway influences immune cell traffick ing and vascular endothelial cell func tion, mechanismbased potential adverse events should be considered for transla tional approaches.
